Sonar Launches SonarQube 9.9 LTS to Help Organizations Achieve a State of Clean Code
7.2.2023 14:00:00 EET | Business Wire | Press release
SonarSource, the leading provider of Clean Code solution, today launched SonarQube 9.9 Long-Term Support (LTS). The new release empowers organizations to achieve the Clean Code state quickly, securely, and at scale. With accelerated pull request analysis, support for building and deploying secure cloud-native applications, sophisticated enterprise-grade capabilities, and many innovations related to the detection engine and contextual education, SonarQube 9.9 LTS supercharges organizations to deliver new business value and keep their software a long-term asset.
“Sonar has greatly helped us benchmark and standardize the quality of our codebase - and the LTS makes it much easier for us to deliver Clean Code. The integration with Azure DevOps from a project-to-project perspective as well as the token lifecycle management will be greatly appreciated by our admins and will help streamline our process,” said Stefan Euripidou, Enterprise Architect for DevOps and CICD at Vodafone Group.
Clean Code is essential for every organization competing in today’s digital-driven economy. Poor quality software costs businesses over $2 trillion a year in the US alone, hampering service quality, brand reputation, worker productivity, and employee retention. Code is the difference between good and bad software. Sonar’s latest 9.9 LTS release introduces key capabilities to enable enterprises to build better software in a sustained manner.
“Our mission is to equip organizations with the solution and methodology to achieve a state of Clean Code, making all code fit for development and production. When companies embrace Clean Code practices, they can derive more from their software, minimize risks, and ensure that their software continues to stay valuable,” said Olivier Gaudin, Founder and CEO of SonarSource. “SonarQube 9.9 LTS was designed to not only provide immediate value to our users for their current development but to steadily drive organizations toward a state of Clean Code in a way that’s predictable, reliable, and sustainable.”
Key release innovations
Pull Request Analyzed in Minutes
SonarQube 9.9 LTS provides a significant speed boost for Pull Request (PR) analysis. PRs are now analyzed more than twice as fast, while still providing the same high-precision results. With the implementation of incremental analysis and server-side caching, analysis is more efficient. As developers write and commit code, Pull Request analysis is an important step in merging new code changes to the main branch. Faster analysis means a more efficient software development lifecycle, as developers spend less time waiting and more time delivering business critical features.
Secure Cloud Native Applications
As applications move to the cloud, organizations must ensure the security of not only the source code, but also their configuration files and deployments. SonarQube 9.9 LTS delivers in-depth analysis capabilities to detect ‘secrets’ in code, bad practices, and vulnerabilities so that developers can build and deploy secure cloud native applications. The release adds support for major cloud providers – AWS, Google Cloud, Microsoft Azure, and their underlying technologies – serverless and SAM frameworks, AWS Cloud Development Kit, Infrastructure-as-Code tools (Terraform and Cloudformation), and containerization tools with Kubernetes and Docker. With these additions, organizations can be sure that their cloud native apps are as secure as their traditional on-prem apps.
Enterprise-grade features for Coding at Scale
SonarQube 9.9 LTS introduces stronger access management, administration, governance, and reporting capabilities, enabling organizations to better manage the security and administration of their SonarQube instance and their portfolio of code assets. Chief among these new features are advanced security and compliance reporting, project and portfolio reporting, secure token handling, SCIM integration for user management, and more. Customers using the Data Center Edition can now deploy SonarQube clusters with Kubernetes. Together, these reporting, authentication and operational improvements make it easier to use, secure, and manage SonarQube instances than ever before.
“The latest SonarQube release introduces a variety of critical new features. Not only will we benefit from the new Terraform scan support, but we will also use the enhanced reporting and administration capabilities to strengthen our Quality Gates and streamline communication efforts,” said Vojtech Varga, Service Manager at Siemens AG. “Sonar’s LTS is an opportunity for us to access the latest fixes and features to ensure that we continue to operate with the highest-quality code.”
Increased Detection of all Issue Types; Rich Educational Guidance
Continued innovation in the detection engine allows for improved precision, speed, accuracy, and coverage of all issue types. Users can find and fix more issues in their code. And this LTS release brings in rich educational content to make taint analysis rules easy to understand and contextual to the users’ code and framework – continuing the advancement of the company’s education initiative.
Clean as You Code, the Sustainable Approach to Clean Code
Sonar is a strong proponent of deploying compliant quality gates that will progressively drive organizations to reach a state of Clean Code. This LTS release adds enhancements to the quality gate user experience to help everyone implement and practice Clean as You Code. Quality gates that are not compliant with this methodology can be easily identified and updated.
SonarQube 9.9 LTS is now available for everyone. Read more in the full release announcement and download the LTS for your edition here.
About SonarSource
Sonar empowers developers and organizations to systematically achieve a state of Clean Code so that all code is fit for development and production. By applying the Sonar Clean as You Code methodology, organizations minimize risk, reduce technical debt, and derive more value from their software in a predictable and sustainable way.
The open source and commercial Sonar solution – SonarLint, SonarCloud, and SonarQube – supports over 30 programming languages, frameworks, and infrastructure technologies. Trusted by more than 400,000 organizations globally to clean more than half a trillion lines of code, Sonar is integral to delivering better software.
To learn more about SonarSource, please visit https://www.sonarsource.com/company/about/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005514/en/
Contact information
Media Contact
Jordan Tewell
10Fold for SonarSource
415-666-6066
sonarsource@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
